KDR and neoplasm: In preclinical glioblastoma models, it has been demonstrated that simultaneous suppression of angiopoietin-2 and VEGFR increases survival time via diverse mechanisms, including the normalization of vascular function, reduction in tumor burden, and modification of macrophage phenotype [212].